SLC5A2 and metabolic dysfunction-associated steatotic liver disease: <h4>Objective</h4>To evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).<h4>Design</h4>A network meta-analysis.<h4>Data sources</h4>PubMed, Embase, Cochrane Library, and Web of Science databases from their inception until September 1, 2021.<h4>Eligibility criteria for selecting studies</h4>Randomized controlled trials (RCTs) comparing the effects of four different drugs in patients with NAFLD were included.